{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06056583",
            "orgStudyIdInfo": {
                "id": "STUDY00018397"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01HD112282",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01HD112282"
                }
            ],
            "organization": {
                "fullName": "University of Washington",
                "class": "OTHER"
            },
            "briefTitle": "Drug Excretion in Breast Milk",
            "officialTitle": "Postpartum Activity and Expression of BCRP and OCT1 Drug Transporters in the Mammary Gland",
            "therapeuticArea": [
                "Other"
            ],
            "study": "drug-excretion-in-breast-milk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-14",
            "studyFirstSubmitQcDate": "2023-09-20",
            "studyFirstPostDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Mary Hebert",
                "investigatorTitle": "Professor: Pharmacy; Adjunct Professor, Obstetrics & Gynecology",
                "investigatorAffiliation": "University of Washington"
            },
            "leadSponsor": {
                "name": "University of Washington",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This is a prospective, non-randomized, phase I study design evaluating the in vivo activities and expression of OCT1 and BCRP in mammary gland of lactating women at three time points postpartum.",
            "detailedDescription": "Each woman will receive a single oral dose of cimetidine 200 mg on each of 3 study days (3-5 weeks, 3-4 months, and 6-8 months postpartum) followed by serial collection of blood, urine and breast milk samples over 12-hours. Cimetidine concentrations will be assay using a validated LC/MS/MS assay. Subjects will be genotyped for OCT1 and BCRP. Mammary epithelial cells will be isolated from breast milk and transporter expression will be quantified. Each woman will serve as her own control."
        },
        "conditionsModule": {
            "conditions": [
                "Lactation"
            ],
            "keywords": [
                "breast milk",
                "lactation",
                "cimetidine",
                "proteomics",
                "OCT1",
                "BCRP",
                "OCTN2",
                "PEPT2",
                "ENT1",
                "CNT3",
                "MRP1",
                "OATP2B1",
                "OATP3A1",
                "OCT2",
                "postpartum",
                "pharmacokinetics"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "This is a phase 1 study design of an approved drug to evaluate the time-course for the expression and activity of OCT1 and BCRP in the mammary gland 3-5 weeks, 3-4 months and 6-8 months postpartum.",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Healthy Lactating Women",
                    "type": "OTHER",
                    "description": "Healthy Lactating Women will be studied on 3 study days and serve as their own control.",
                    "interventionNames": [
                        "Drug: Cimetidine 200 MG"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cimetidine 200 MG",
                    "description": "Cimetidine will serve as the probe drug",
                    "armGroupLabels": [
                        "Healthy Lactating Women"
                    ],
                    "otherNames": [
                        "Tagamet"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mammary clearance of cimetidine",
                    "description": "Cimetidine excretion into breast milk at three postpartum stages",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Mammary epithelial cell expression of BCRP",
                    "description": "BCRP protein expression in MECs at three postpartum stages",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Mammary epithelial cell expression of OCT1",
                    "description": "OCT1 protein expression in MECs at three postpartum stages",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cimetidine relative infant dose and infant concentration",
                    "description": "cimetidine relative infant dose (RID) and infant concentration",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Relationship between OCT1 expression and activity",
                    "description": "Effect of time postpartum on OCT1 protein expression in MECs and correlation with cimetidine mammary CL",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine CL/F",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine renal CL",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine renal secretion CL",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine mammary CL",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine AUC",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine Cmax",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine Tmax",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine half-life",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine apparent oral volume of distribution",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Maternal cimetidine PK",
                    "description": "Effects of time postpartum on cimetidine elimination rate constant",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                },
                {
                    "measure": "Relationship between BCRP expression and activity",
                    "description": "Effect of time postpartum on BCRP protein expression in MECs and correlation with cimetidine mammary CL",
                    "timeFrame": "3-5 weeks, 3-4 months and 6-8 months postpartum"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Study participants will include: healthy, lactating or pregnant and planning to breastfeed their infant, between 18-50 years of age, female and their nursing infant 3 weeks-8 months of age.\n\nExclusion Criteria:\n\n* \u2022 Age \\<18 or \\> 50 years old.\n\n  * Smokers\n  * Following multiple gestation (twins, triplets etc.)\n  * Allergy to cimetidine\n  * Pregnancy\n  * Receiving medications that could lead to a drug interaction e.g.\n\n    * A: antacids, alprazolam, amphetamines, atazanavir, acalabrutinib, alosetron, amiodarone, amitriptyline, azelastine, amoxapine, alfuzosin,\n    * B: bisacodyl, bupropion, bosutinib,\n    * C: citalopram, chloroquine, codeine, clozapine, carmustine, clopidogrel, cyclosporine, carvedilol, cannabis, cefpodoxime, ceftibuten, clomipramine, cefditoren, chlordiazepoxide, chlorpromazine, cholecalciferol, cisapride, clonazepam, clorazepate, clomethiazole, carbamazepine,\n    * D: dofetilide, dihydrocodeine, duloxetine, delavirdine, dasatinib, domperidone, dothiepin, dilevalol, diltiazem, dutasteride, desipramine, doxepin, diazepam,\n    * E: escitalopram, epirubicin, eliglustat, estazolam, ethanol (on study day), ergocalciferol,\n    * F: fezolinetant, fluorouracil, finerenone, fexinidazole, flecainide, fluconazole, flurazepam, fosamprenavir, femoxetine,\n    * G: gefitinib, glipizide, glyburide, gliclazide, glimepiride,\n    * H: hydroxychloroquine, halazepam,\n    * I: infigratinib, imipramine, itraconazole,\n    * K: ketoconazole,\n    * L: ledipasvir, lornoxicam, labetalol, lidocaine, levoketoconazole, levomethadyl, lomitapide, loratadine,\n    * M: meperidine, morphine, mirtazapine, midazolam, metformin, metoclopramide, memantine, metronidazole, moclobemide,\n    * N: neratinib, nicotine, nebivolol, nisoldipine, nifedipine, nortriptyline, nimodipine, nicardipine, nilotinib, nitrazepam, nilvadipine, nitrendipine,\n    * O: oxycodone, octreotide, oxymorphone,\n    * P: posaconazole, piperaquine, pazopanib, pentoxifylline, paroxetine, phenytoin, pramipexole, propranolol, procainamide, phenindione, perfloxacin, praziquantel, protriptyline, prazepam, pontinib,\n    * Q: quinidine, quazepam, quinine,\n    * R: rilpivirine, roflumilast, risperidone, risedronate,\n    * S: succinylcholine, selpercatinib, sirolimus, secretin, sotorasib, sparsentan, sofobuvir, saquinavir, sertraline, sucralfate, sildenafil,\n    * T: terbinafine, tramadol, theophylline, tacrolimus, tizanidine, tolazoline, trimetrexate, tocainide, tamsulosin, timolol, tacrine, tolbutamide, trimipramine, tamoxifen, trimazosin, tinidazole, triazolam,\n    * V: vismodegib, verapamil, velpatasvir, venlafaxine, vardenafil,\n    * W: warfarin,\n    * Z: zalcitabine, zaleplon, zolmitriptan\n  * BCRP inhibitors: dasatinib, celecoxib, erlotinib, lopinavir, fostamatinib, docetaxel, barcitinib, imatinib, gefitnib, venetoclax, sunitinib, elacridar, Palbociclib, regorafenib, rucaparib, nilotinib, sorafenib, vemurafenib, afatinib, nelfinavir, paclitaxel, quercetin and alectinib\n  * BCRP inducers: venlafaxine, and dovitinib\n  * OCT inhibitors: trimethoprim, ranitidine, codeine, rocuronium, ganciclovir, acyclovir, dinoprostone, progesterone, prazosin, phenoxybenzamine, phenformin, procainamide, nicotine, choline, verapamil, quinine, pancuronium, disopyramide, desipramine, guanidine, probenecid, saquinavir, nelfinavir, chlorpheniramine, indinavir, reserpine, rucaparib, estradiol, pitolisant, choline, quinidine, amantadine, dexchlorpheniramine, doxazosin, efavirenz, nevirapine, clopidogrel, dacomitinib, gilteritinib, palbociclib, linagliptin, nintedanib, dronedarone, lasmiditan, formoterol, guanfacine, salmeterol, levofloxacin, osilodrostat, lurbinectedin, tirbanibulin cyproheptadine, infigratinib, atagepant, asciminib, abrocitinib, pacritinib, olaparib, tepotinib, tafenoquine, propranolol, oxprenolol, metoprolol, quinine, thiamine, norepinephrine, imipramine, grepafloxacine, amantadine, metformin, desipramine, famotidine, probenecid, cisplatin, quinacrine, amiloride, epinephrine, disopyramide, diphenhydramine, imatinib, flurazepam, bupropion, amiodarone, clopidogrel, cocaine, lamotrigine\n  * OCT inducers: none identified",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "maximumAge": "50 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mary Hebert, PharmD, FCCP",
                    "role": "CONTACT",
                    "phone": "206-616-5016",
                    "email": "mhebert@uw.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Mary Hebert, PharmD, FCCP",
                    "affiliation": "University of Washington",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Washington",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mary F Hebert, PharmD",
                            "role": "CONTACT",
                            "phone": "206-616-5016",
                            "email": "mhebert@uw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "We are committed to share data with the academic community and researcher-at-large. We will adhere to the NIH Grant Policy on Sharing Research Data and Resources. That is, after final data collection and analysis and after full peer review is performed on our data, the de-identified data generated by this project will be made available when requested by the academic community and researchers-at-large contingent upon Material Transfer Agreements with the University of Washington.",
            "infoTypes": [
                "CSR"
            ],
            "timeFrame": "After peer review and publication of data.",
            "accessCriteria": "We are committed to share data with the academic community and researcher-at-large. We will adhere to the NIH Grant Policy on Sharing Research Data and Resources. That is, after final data collection and analysis and after full peer review is performed on our data, the de-identified data generated by this project will be made available when requested by the academic community and researchers-at-large contingent upon Material Transfer Agreements with the University of Washington."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002927",
                    "term": "Cimetidine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000897",
                    "term": "Anti-Ulcer Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000006635",
                    "term": "Histamine H2 Antagonists"
                },
                {
                    "id": "D000006633",
                    "term": "Histamine Antagonists"
                },
                {
                    "id": "D000018494",
                    "term": "Histamine Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000065609",
                    "term": "Cytochrome P-450 CYP1A2 Inhibitors"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6165",
                    "name": "Cimetidine",
                    "asFound": "Peripheral vein",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4188",
                    "name": "Antacids",
                    "relevance": "LOW"
                },
                {
                    "id": "M4219",
                    "name": "Anti-Ulcer Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9708",
                    "name": "Histamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M9711",
                    "name": "Histamine H2 Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M212144",
                    "name": "Histamine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M9709",
                    "name": "Histamine Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}